Journal ArticleDOI
Trend towards decreased survival in patients infected with HIV resistant to zidovudine.
Reads0
Chats0
TLDR
The survival of 35 patients with AIDS or advanced HIV infection on treatment with zidovudine was related to the viral sensitivity to the drug and to the CD4+ cell count and large studies of combination or alternation therapy with several anti-HIV drugs should be given high priority.Abstract:
The survival of 35 patients with AIDS or advanced HIV infection on treatment with zidovu-dine was related to the viral sensitivity to the drug and to the CD4+ cell count. 14 patients died, the survivors were followed up for an average of 804 days. In a univariate Cox model, survival was strongly related to Iog IC90 (p = 0.0003) and to the CD4+ count (p = 0.0002). In a bivariate model, Iog IC90 and the CD4+ count contributed to the prediction of survival (p = 0.12 and 0.06, respectively). Large studies of combination or alternation therapy with several anti-HIV drugs should be given high priority.read more
Citations
More filters
Journal ArticleDOI
Lack of synergy in the inhibition of HIV-1 reverse transcriptase by combinations of the 5'-triphosphates of various anti-HIV nucleoside analogs.
TL;DR: Results indicated that synergistic inhibition of the HIV-1 reverse transcriptase is not responsible for the synergistic antiviral activity seen in cell culture with combinations of these nucleoside analogs.
Journal Article
A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome
TL;DR: In this article, a randomized controlled trial was conducted to evaluate the efficacy and safety of a reduced dose of zidovudine for patients with advanced disease caused by the human immunodeficiency virus type 1 (HIV).
Antagonistic evolutionary pathways of hiv-1 resistance to nucleoside reverse transcriptase inhibitors: a virological, biochemical and clinical investigation
TL;DR: It is proposed that K65R and TAMs represent two different pathways of NRTI resistance that exhibit bi-directional phenotypic antagonism and counterselection in vivo and will help to optimize current and future therapy for HIV-1 infection.
References
More filters
Journal ArticleDOI
The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind placebo-controlled trial.
Margaret A. Fischl,Douglas D. Richman,M. H. Grieco,M. S. Gottlieb,Paul A. Volberding,Oscar L. Laskin,John M. Leedom,Jerome E. Groopman,Donna Mildvan,Robert T. Schooley +9 more
TL;DR: It is demonstrated that AZT administration can decrease mortality and the frequency of opportunistic infections in a selected group of subjects with AIDS or AIDS-related complex, at least over the 8 to 24 weeks of observation in this study.
Journal ArticleDOI
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy
TL;DR: It would be premature to alter any treatment protocols for HIV-infected individuals at present, as it cannot be determined from this small sample of patients whether development of a less sensitive virus phenotype results in clinical resistance.
Journal ArticleDOI
A double‐blind, placebo‐controlled trial
Robert S. Pinals,Robert S. Pinals,Robert S. Pinals,Stanley B. Kaplan,Stanley B. Kaplan,Jeffrey G. Lawson,Jeffrey G. Lawson,Bonnie Hepburn,Bonnie Hepburn +8 more
TL;DR: Results confirm previous findings that suppression of rheumatoid synovitis may be induced by SSZ, within 2 months after full maintenance doses are reached.
Journal ArticleDOI
Zidovudine in Asymptomatic Human Immunodeficiency Virus Infection: A Controlled Trial in Persons with Fewer Than 500 CD4-Positive Cells per Cubic Millimeter
Paul A. Volberding,Stephen W. Lagakos,Matthew A. Koch,David K. Booth,Carla Pettinelli,Maureen Myers,Henry H. Balfour,Richard C. Reichman,John Bartlett,Martin S. Hirsch,Robert L. Murphy,W. David Hardy,Ruy Soeiro,Margaret A. Fischl,John G. Bartlett,Thomas C. Merigan,Newton E. Hyslop,Douglas D. Richman,Fred T. Valentine,Lawrence Corey +19 more
TL;DR: Zidovudine is safe and effective in persons with asymptomatic HIV infection and fewer than 500 CD4+ cells per cubic millimeter and additional study will be required to determine whether such treatment will ultimately improve survival for persons infected with HIV.
Journal ArticleDOI
A Randomized Controlled Trial of a Reduced Daily Dose of Zidovudine in Patients with the Acquired Immunodeficiency Syndrome
Margaret A. Fischl,Corette B. Parker,Carla Pettinelli,Michael Wulfsohn,Martin S. Hirsch,Ann C. Collier,Diana Antoniskis,Monto Ho,Douglas D. Richman,Edward Fuchs,Thomas C. Merigan,Richard C. Reichman,Jonathan W. M. Gold,Neal H. Steigbigel,Gifford S. Leoung,Suraiya Rasheed,Anastasios A. Tsiatis +16 more
TL;DR: A randomized controlled trial in 524 subjects who had had a first episode of Pneumocystis carinii pneumonia found that the efficacy and safety of a reduced dose of zidovudine were superior to the standard-treatment group and the low-dose group.
Related Papers (5)
Long-term Mortality in HIV-Positive Individuals Virally Suppressed for > 3 Years With Incomplete CD4 Recovery
Frederik Neess Engsig,Robert Zangerle,Olga Katsarou,François Dabis,Peter Reiss,John Gill,Kholoud Porter,Caroline A. Sabin,Andrew Riordan,Gerd Fätkenheuer,Félix Gutiérrez,François Raffi,Ole Kirk,Murielle Mary-Krause,Christoph Stephan,Patricia García de Olalla,Jodie L. Guest,Hasina Samji,Antonella Castagna,Antonella d'Arminio Monforte,Adriane Skaletz-Rorowski,José Ramos,Giuseppe Lapadula,Cristina Mussini,Lluís Force,Laurence Meyer,Fiona C Lampe,Faroudy Boufassa,Heiner C. Bucher,Stéphane De Wit,Greer A. Burkholder,Ramón Teira,Amy C. Justice,Timothy R. Sterling,Heidi M. Crane,Jan Gerstoft,Jesper Grarup,Margaret T May,Geneviève Chêne,Suzanne M Ingle,Jonathan A C Sterne,Niels Obel +41 more